|
|
|
| Research Progress of Tailored Therapy Guided by Molecular-based Antibiotic Susceptibility Testing of Helicobacter Pylori |
| LIN Kaihao, HUANG Lifang, LI Aimin |
| Nanfang Hospital of Southern Medical University, Guangzhou 510515, China |
|
|
|
|
Abstract The increasing drug resistance rate of Helicobacter pylori causes the eradication rate of empirical therapy to decrease year by year. However, due to the advantages of sensitivity, accuracy, reliability, speed and convenience of molecular-based biological antibiotic susceptibility testing technology, the tailored therapy guided by it has been increasingly recognized and valued. This article systematically reviews and comprehensively analyzes the research progress of tailored treatment effect of molecular-based antibiotic susceptibility testing. At present, molecular-based biological antibiotic susceptibility testing technology are based on polymerase chain reaction (PCR), the detection of Clarithromycin resistance mutations is mainly often used to guide the first treatment in clinic. In general, tailored therapy guided by molecular-based antibiotic susceptibility testing is superior to empirical triple therapy, but is equivalent to empirical bismuth quadruple therapy and concomitant therapy. However, when tailored treatment is performed with bismuth quadruple therapy, the efficacy is superior to empirical bismuth quadruple therapy. Although the molecular-based antibiotic susceptibility testing technology has the defects of limited coverage of antibiotic detection types, invasive sampling, and false-negative risk, the tailored treatment guided by the molecular-based antibiotic susceptibility testing technology can still improve the eradication rate of Helicobacter pylori and reduce the use of unnecessary resistant antibiotics.
|
|
Received: 26 December 2022
|
|
|
|
|
|
|
